Treating primary hypercholesterolaemia and mixed dyslipidaemia (NICE TA393)
Alirocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
Low-density lipoprotein concentrations are persistently above the thresholds specified in table 1 (see NICE TA 393) despite maximal tolerated lipid-lowering therapy. That is, either the maximum dose has been reached or further titration is limited by intolerance (as defined in NICE’s guideline on familial hypercholesterolaemia: identification and management).
The company provides alirocumab with the discount agreed in the patient access scheme.